Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK Comparison of DWJ1563 FDC vs Enavogliflozin and Gemigliptin Loose Combination
NCT05737771Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin and gemigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to Time t and Maximum Plasma Concentration. Status: unknown.
02
Drugs
enavogliflozingemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05737771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737771.